高级检索
邓丹琼, 梁碧玲. 乳腺癌患者临床病理特征与磁共振成像强化率关系[J]. 中国公共卫生, 2016, 32(9): 1255-1257. DOI: 10.11847/zgggws2016-32-09-32
引用本文: 邓丹琼, 梁碧玲. 乳腺癌患者临床病理特征与磁共振成像强化率关系[J]. 中国公共卫生, 2016, 32(9): 1255-1257. DOI: 10.11847/zgggws2016-32-09-32
DENG Dan-qiong, LIANG Bi-ling. Correlation between clinicopathologic characteristics and enhanced rate of breast MRI among breast cancer patients[J]. Chinese Journal of Public Health, 2016, 32(9): 1255-1257. DOI: 10.11847/zgggws2016-32-09-32
Citation: DENG Dan-qiong, LIANG Bi-ling. Correlation between clinicopathologic characteristics and enhanced rate of breast MRI among breast cancer patients[J]. Chinese Journal of Public Health, 2016, 32(9): 1255-1257. DOI: 10.11847/zgggws2016-32-09-32

乳腺癌患者临床病理特征与磁共振成像强化率关系

Correlation between clinicopathologic characteristics and enhanced rate of breast MRI among breast cancer patients

  • 摘要: 目的 了解乳腺癌患者临床病理特征与磁共振成像(MRI)强化率的关系,为乳腺癌的诊断提供参考依据。方法 收集2014年1月-2016年1月在中山大学孙逸仙纪念医院行MRI检查并经病理确诊的103例乳腺癌患者病历资料,分析乳腺癌患者不同临床病理特征与MRI强化率的关系。结果 乳腺癌患者注射对比剂后0.5、1、2、3、4和5 min的MRI强化率分别为(141.40±77.96)%、(166.99±83.99)%、(174.96±84.98)%、(176.59±84.28)%和(171.79±80.61)%;不同临床病理特征乳腺癌患者MRI强化率比较,不同肿瘤大小乳腺癌患者注射对比剂后0.5、1、2、3、4、5 min MRI强化率及不同分子分型、临床分期乳腺癌患者注射对比剂后0.5 min MRI强化率差异均有统计学意义(均P<0.05)。结论 乳腺癌患者的肿瘤大小对注射对比剂后各时间点MRI强化率均有影响,分子分型和临床分期也与MRI强化率有一定关系。

     

    Abstract: Objective To explore the relationship between enhanced rate of breast magnetic resonance imaging (MRI) and clinicopathologic characteristics of breast cancer and to provide references for diagnosis of breast cancer.Methods Medical records of 103 pathologically confirmed female breast cancer patients having received MRI were collected from Sun Yat-sen Memorial Hospital Affiliated to Sun Yat-sen University from January 2014 to January 2016.The correlation between enhanced rate of MRI and clinicopathologic characteristics of breast cancer was analyzed.Results The average MRI enhanced rate of the patients was 141.40±77.96%,166.99±83.99%,174.96±84.98%,176.59±84.28%,171.79±80.61%,and 170.26±79.35% at 0.5,1,2,3,4,and 5 minutes after the injection of contrast agent,respectively.There were significant differences in the MRI enhance rate among the patients with different size of breast cancer at 0.5,1,2,3,4,and 5 minutes and among the patients with various molecular biological type and clinic stage of the tumor at 0.5 minute after the injection of contrast agent (P<0.05 for all).Conclusion The size of breast cancer has impacts on the MRI enhanced rate at various time points after the injection of contrast agent and molecular type and clinical stages also correlate with the MRI enhanced rate among female breast cancer patients.

     

/

返回文章
返回